PRECISION OPTICS CORPORATION, INC. POCI
advanced optical instruments since 1982, and we operate primarily in two key market segments: medical devices and advanced defense/aerospace products. Within our proprietary optical and imaging technology, our unique custom designs, expert manufacturing
capabilities, and advanced engineering and development capabilities have generated traditional endoscopes and endocouplers, digital
imaging endoscopes using CMOS sensor technology, some designed and manufactured for single-use, as well as other, more advanced,
custom imaging and illumination products for our customers' use in minimally invasive surgical procedures. We design and
Last close
4.33
2026-10-23
Market cap
$47.4M
2026-03-31 share count
52-week range
3.55 - 6.15
Valuation FY2025 figures against the last close
P/S2.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.85
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.1M | $19.1M | $21.0M | $15.7M | $10.7M | $9.9M | $6.8M | $4.0M | $3.2M | $3.9M |
| Cost of revenue | $15.7M | $13.3M | $13.3M | $10.8M | $7.2M | $6.6M | $4.7M | $2.6M | $2.4M | $3.0M |
| Gross profit | $3.4M | $5.8M | $7.7M | $4.9M | $3.4M | $3.4M | $2.1M | $1.5M | $773.7K | $942.0K |
| R&D | $1.2M | $981.8K | $992.4K | $666.5K | $624.3K | $886.1K | $505.3K | $456.4K | $464.2K | $478.3K |
| SG&A | $7.8M | $7.5M | $7.4M | $5.6M | $3.7M | $3.9M | $2.1M | $1.4M | $1.3M | $1.6M |
| Total operating expenses | $9.0M | $8.5M | $8.4M | $6.4M | $4.3M | $4.8M | $2.7M | $1.8M | $1.8M | $2.0M |
| Operating income | -$5.6M | -$2.7M | -$638.5K | -$1.5M | -$905.6K | -$1.4M | -$612.5K | -$348.6K | -$1.0M | -$1.1M |
| Interest expense | $227.0K | $225.1K | $218.9K | $155.7K | $5.3K | $1.0K | $1.4K | $1.9K | $3.1K | $469 |
| Pre-tax income | -$5.8M | -$2.9M | -$142.7K | -$927.5K | -$101.9K | -$1.4M | -$614.0K | -$350.5K | -$1.0M | -$1.0M |
| Income tax | $1.9K | $1.9K | $1.9K | $952 | $912 | $2.2K | $912 | $912 | $912 | $912 |
| Net income | -$5.8M | -$3.0M | -$144.6K | -$928.4K | -$102.8K | -$1.4M | -$614.9K | -$351.4K | -$1.0M | -$1.0M |
| EPS, basic | -0.85 | -0.49 | -0.03 | -0.18 | -0.01 | — | -0.05 | -0.04 | -0.12 | -0.15 |
| EPS, diluted | -0.85 | -0.49 | -0.03 | -0.18 | -0.01 | -0.11 | -0.05 | -0.04 | -0.12 | -0.15 |
| Shares, diluted (wtd. avg.) | 6.8M | 6.1M | 5.7M | 5.3M | 13.3M | 13.0M | 11.5M | 9.8M | 8.3M | 7.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.8M | $405.3K | $2.9M | $605.7K | $861.6K | $1.1M | $2.3M | $402.7K | $118.4K | $50.1K |
| Receivables | $4.3M | $3.5M | $3.9M | $2.7M | $1.9M | $1.5M | $2.2M | $796.9K | $468.5K | $750.4K |
| Inventory | $3.6M | $2.9M | $2.8M | $3.0M | $1.9M | $2.2M | $1.7M | $1.1M | $1.1M | $1.1M |
| Total current assets | $10.1M | $7.1M | $9.9M | $6.5M | $4.8M | $4.9M | $6.4M | $2.4M | $1.7M | $2.0M |
| Property, plant and equipment | $533.8K | $493.6K | $433.5K | $627.5K | $594.3K | $503.1K | $383.0K | $49.5K | $72.3K | $78.2K |
| Goodwill | $8.8M | $8.8M | $8.8M | $8.8M | $687.7K | $687.7K | $687.7K | $0 | — | — |
| Other intangibles | $232.5K | $286.6K | $265.1K | $229.4K | $141.7K | $95.2K | $54.1K | $47.3K | $30.1K | $22.9K |
| Total assets | $19.8M | $16.9M | $19.7M | $16.7M | $6.3M | $6.4M | $7.5M | $2.5M | $1.8M | $2.1M |
| Accounts payable | $2.9M | $1.4M | $2.4M | $2.2M | $1.2M | $1.1M | $1.2M | $703.5K | $695.0K | $1.2M |
| Short-term debt | $577.9K | $276.9K | $513.3K | $367.7K | $0 | — | — | — | — | — |
| Total current liabilities | $6.2M | $4.9M | $5.3M | $4.6M | $2.5M | $3.1M | $3.6M | $1.9M | $1.2M | $1.5M |
| Long-term debt | $1.3M | $1.9M | $2.2M | $2.0M | $0 | — | — | — | — | — |
| Total liabilities | $7.5M | $6.8M | $7.7M | — | — | — | — | — | — | — |
| Retained earnings | -$57.0M | -$51.2M | -$48.2M | -$48.1M | -$47.2M | -$47.1M | -$45.6M | -$45.0M | -$44.7M | -$43.7M |
| Total equity | $12.3M | $10.1M | $12.0M | $9.0M | $3.4M | $2.8M | $3.4M | $564.0K | $558.4K | $587.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.5M | -$2.7M | -$81.1K | -$933.4K | $46.5K | -$592.5K | -$1.0M | $100.7K | -$667.4K | -$876.3K |
| Depreciation and amortisation | $212.4K | $212.4K | $210.7K | $190.2K | $146.8K | $112.2K | $38.6K | $27.2K | $33.7K | $25.9K |
| Stock-based compensation | $1.5M | $959.8K | $919.0K | $915.5K | $733.9K | $502.3K | $263.3K | $52.3K | $201.6K | $241.4K |
| Capital expenditure | $227.2K | $272.4K | $16.8K | $113.2K | $75.9K | $119.2K | $140.0K | $4.4K | $27.7K | $4.4K |
| Investing cash flow | -$233.5K | -$293.9K | -$52.5K | -$407.8K | -$122.4K | -$1.6M | -$40.3K | -$21.6K | -$33.4K | $24.1K |
| Financing cash flow | $5.1M | $456.3K | $2.5M | $1.1M | -$197.2K | $1.0M | $3.0M | $205.3K | $769.2K | $661.2K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-25-007809.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9M | $3.2M | $4.0M | $6.8M | $9.9M | $10.7M | $15.7M | $21.0M | $19.1M | $19.1M |
| Gross profit | $942.0K | $773.7K | $1.5M | $2.1M | $3.4M | $3.4M | $4.9M | $7.7M | $5.8M | $3.4M |
| Net income | -$1.0M | -$1.0M | -$351.4K | -$614.9K | -$1.4M | -$102.8K | -$928.4K | -$144.6K | -$3.0M | -$5.8M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
- Shareholder vote Item 5.07
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| LIVN | LivaNova PLC | $4.46B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.89B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |